BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37793461)

  • 1. The Notch signaling pathway in desmoid tumor: Recent advances and the therapeutic prospects.
    Zheng C; Huang J; Xu G; Li W; Weng X; Zhang S
    Biochim Biophys Acta Mol Basis Dis; 2024 Jan; 1870(1):166907. PubMed ID: 37793461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular pathogenesis of desmoid tumor and the role of γ-secretase inhibition.
    Federman N
    NPJ Precis Oncol; 2022 Sep; 6(1):62. PubMed ID: 36068332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of the Gamma Secretase Inhibitor AL101 in Desmoid Tumors: A Case Report of 2 Adult Cases.
    Chan D; Kaplan J; Gordon G; Desai J
    Curr Oncol; 2021 Sep; 28(5):3659-3667. PubMed ID: 34590610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the Notch pathway: A potential therapeutic approach for desmoid tumors.
    Shang H; Braggio D; Lee YJ; Al Sannaa GA; Creighton CJ; Bolshakov S; Lazar AJ; Lev D; Pollock RE
    Cancer; 2015 Nov; 121(22):4088-96. PubMed ID: 26349011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Pathogenesis of Sporadic Desmoid Tumours and Its Implications for Novel Therapies: A Systematised Narrative Review.
    McLean TD; Duchi S; Di Bella C
    Target Oncol; 2022 May; 17(3):223-252. PubMed ID: 35446005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desmoid-type fibromatosis: Current therapeutic strategies and future perspectives.
    Ibrahim R; Assi T; Khoury R; Ngo C; Faron M; Verret B; Lévy A; Honoré C; Hénon C; Le Péchoux C; Bahleda R; Le Cesne A
    Cancer Treat Rev; 2024 Feb; 123():102675. PubMed ID: 38159438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current management and recent progress in desmoid tumors.
    Zhou MY; Bui NQ; Charville GW; Ghanouni P; Ganjoo KN
    Cancer Treat Res Commun; 2022; 31():100562. PubMed ID: 35460976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gamma-Secretase Inhibitor IX (GSI) Impairs Concomitant Activation of Notch and Wnt-Beta-Catenin Pathways in CD44
    Barat S; Chen X; Cuong Bui K; Bozko P; Götze J; Christgen M; Krech T; Malek NP; Plentz RR
    Stem Cells Transl Med; 2017 Mar; 6(3):819-829. PubMed ID: 28186678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of gamma-secretase inhibitor nirogacestat (PF-03084014) in desmoid tumor: Report of four pediatric/young adult cases.
    Takahashi T; Prensner JR; Robson CD; Janeway KA; Weigel BJ
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28636. PubMed ID: 32762028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors.
    Gounder M; Ratan R; Alcindor T; Schöffski P; van der Graaf WT; Wilky BA; Riedel RF; Lim A; Smith LM; Moody S; Attia S; Chawla S; D'Amato G; Federman N; Merriam P; Van Tine BA; Vincenzi B; Benson C; Bui NQ; Chugh R; Tinoco G; Charlson J; Dileo P; Hartner L; Lapeire L; Mazzeo F; Palmerini E; Reichardt P; Stacchiotti S; Bailey HH; Burgess MA; Cote GM; Davis LE; Deshpande H; Gelderblom H; Grignani G; Loggers E; Philip T; Pressey JG; Kummar S; Kasper B
    N Engl J Med; 2023 Mar; 388(10):898-912. PubMed ID: 36884323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor-initiating cells.
    Saito N; Fu J; Zheng S; Yao J; Wang S; Liu DD; Yuan Y; Sulman EP; Lang FF; Colman H; Verhaak RG; Yung WK; Koul D
    Stem Cells; 2014 Jan; 32(1):301-12. PubMed ID: 24038660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving strategies for management of desmoid tumor.
    Riedel RF; Agulnik M
    Cancer; 2022 Aug; 128(16):3027-3040. PubMed ID: 35670122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Pharmacotherapeutic Agents in Children with Desmoid Tumors.
    Douglass DP; Navid F; Weiss AR
    Paediatr Drugs; 2022 Sep; 24(5):433-445. PubMed ID: 35902507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second generation γ-secretase modulators exhibit different modulation of Notch β and Aβ production.
    Wanngren J; Ottervald J; Parpal S; Portelius E; Strömberg K; Borgegård T; Klintenberg R; Juréus A; Blomqvist J; Blennow K; Zetterberg H; Lundkvist J; Rosqvist S; Karlström H
    J Biol Chem; 2012 Sep; 287(39):32640-50. PubMed ID: 22851182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similar mechanisms regulated by gamma-secretase are involved in both directions of the bi-directional Notch-Delta signaling pathway as well as play a potential role in signaling events involving type 1 transmembrane proteins.
    Nakayama K; Nagase H; Hiratochi M; Koh CS; Ohkawara T
    Curr Stem Cell Res Ther; 2008 Dec; 3(4):288-302. PubMed ID: 19075758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proton myo-inositol cotransporter is a novel γ-secretase associated protein that regulates Aβ production without affecting Notch cleavage.
    Teranishi Y; Inoue M; Yamamoto NG; Kihara T; Wiehager B; Ishikawa T; Winblad B; Schedin-Weiss S; Frykman S; Tjernberg LO
    FEBS J; 2015 Sep; 282(17):3438-51. PubMed ID: 26094765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. γ-Secretase-regulated signaling typified by Notch signaling in the immune system.
    Nagase H; Nakayama K
    Curr Stem Cell Res Ther; 2013 Sep; 8(5):341-56. PubMed ID: 23957936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of γ-secretase/Notch pathway as a potential therapy for reversing cancer drug resistance.
    Feng M; Santhanam RK; Xing H; Zhou M; Jia H
    Biochem Pharmacol; 2024 Feb; 220():115991. PubMed ID: 38135129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design.
    Wei P; Walls M; Qiu M; Ding R; Denlinger RH; Wong A; Tsaparikos K; Jani JP; Hosea N; Sands M; Randolph S; Smeal T
    Mol Cancer Ther; 2010 Jun; 9(6):1618-28. PubMed ID: 20530712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant model.
    Arcaroli JJ; Quackenbush KS; Purkey A; Powell RW; Pitts TM; Bagby S; Tan AC; Cross B; McPhillips K; Song EK; Tai WM; Winn RA; Bikkavilli K; Vanscoyk M; Eckhardt SG; Messersmith WA
    Br J Cancer; 2013 Aug; 109(3):667-75. PubMed ID: 23868008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.